Hi everyone,
I was wondering if anyone here was thinking about toxic substances present in insulin formulations. For example, Novorapid contains 1.5 mg/ml of phenol and 1.72 mg/ml of metacresol. Both of these substances are very toxic, and for someone who is injecting 20 units of insulin per day, means also 300 ppm of phenol per day and 344 ppm of m-cresol.
Here is the study that was dealing with cell death induced with these substances.
http://www.sciencedirect.com/science/article/pii/S2214750014001541
On the other hand, I understand that for the purification step, in the production of insulin, phenol is used to separate protein from DNA, but there must be an alternative which is safer.
Hi everyone,
I was wondering if anyone here was thinking about toxic substances present in insulin formulations. For example, Novorapid contains 1.5 mg/ml of phenol and 1.72 mg/ml of metacresol. Both of these substances are very toxic, and for someone who is injecting 20 units of insulin per day, means also 300 ppm of phenol per day and 344 ppm of m-cresol.
Here is the study that was dealing with cell death induced with these substances.
http://www.sciencedirect.com/science/article/pii/S2214750014001541
On the other hand, I understand that for the purification step, in the production of insulin, phenol is used to separate protein from DNA, but there must be an alternative which is safer.
The bigger question is whether it is really causing any issues. While this research establishes that the preservatives and sterility providers are vaguely toxic, it doesn't look at the in situ conditions and the question as to whether it is toxicity or healing that causes a requirement to change sets.
And given the percentage of T1s using CSII compared with the number using injections, it will remain a low priority. As it stands, this is a first world problem with limited value in large amounts of investigation. I'm sure it will continue but I don't expect fast progress.Agree, but at present we just dont know - the sciencedirect article references a whole lot of interesting studies, and by following the references in some of these I have realised how much more complex the infusion site issues in particular may be, especially over the long term, and how much they are being studied.
Hi everyone,
I was wondering if anyone here was thinking about toxic substances present in insulin formulations. For example, Novorapid contains 1.5 mg/ml of phenol and 1.72 mg/ml of metacresol. Both of these substances are very toxic, and for someone who is injecting 20 units of insulin per day, means also 300 ppm of phenol per day and 344 ppm of m-cresol.
Here is the study that was dealing with cell death induced with these substances.
http://www.sciencedirect.com/science/article/pii/S2214750014001541
On the other hand, I understand that for the purification step, in the production of insulin, phenol is used to separate protein from DNA, but there must be an alternative which is safer.
Hi everyone,
I was wondering if anyone here was thinking about toxic substances present in insulin formulations. For example, Novorapid contains 1.5 mg/ml of phenol and 1.72 mg/ml of metacresol. Both of these substances are very toxic, and for someone who is injecting 20 units of insulin per day, means also 300 ppm of phenol per day and 344 ppm of m-cresol.
Here is the study that was dealing with cell death induced with these substances.
http://www.sciencedirect.com/science/article/pii/S2214750014001541
On the other hand, I understand that for the purification step, in the production of insulin, phenol is used to separate protein from DNA, but there must be an alternative which is safer.
For me, the numbers don't add up:-
ISO Constants:-
1 ppm = 1mg/L
1L = 1000mL
1mL = 100 units (insulin)
The question is whether it removes the proteins in a way that they can be reused in insulin in an effective manner.I am sure that phenol m-cresol are not the only preservatives available and they are probably used for cheap separation od protein from the DNA of the species used to make it (bacteria). For the rest, I can do some research. Some other resin is a possibility, like this one used in lab
https://advansta.com/products/RapidClean/
And given the percentage of T1s using CSII compared with the number using injections, it will remain a low priority. As it stands, this is a first world problem with limited value in large amounts of investigation. I'm sure it will continue but I don't expect fast progress.
Are you a mother of a newly diagnosed child? I'm not saying you are looking for reasons for something but you seem to be focussing on a very narrow subset of the reasons for a correlation between cancer and Type 1Diabetes. There's a major discussion here: http://care.diabetesjournals.org/content/33/7/1674.long on this topic and you have to also considered the changes in th e body caused by the loss of the beta cells plus the side effects of basic hyperinsulinemia due to exogenous insulin. It's not as straightforward as a single ingredient in an insulin analogue.I was searching for an insulin that has less phenol and/or m-cresol and I found none, regardles of application method (injection, CSII, IV). No wonder why ghe risk of cancer in diabetic patients is incerased.
Calculation:
concentration of phenol in Novorapid is
1,5 mg/ml so in 1 ml (100 units) you have 1,5 mg of phenol or 1500 mg/l which is 1500 ppm, so in 100 units (1ml) there is 1500 ppm of phenol. Seems a lot.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?